# EBAG9

## Overview
EBAG9, or estrogen receptor binding site associated antigen 9, is a gene that encodes a protein involved in the regulation of immune responses and intracellular trafficking. The protein, also referred to as EBAG9, is primarily localized in the Golgi apparatus and associated vesicles, suggesting a role in protein processing and trafficking within the cell (Reimer2005Reevaluation). Functionally, EBAG9 is categorized as a regulatory protein that interacts with components of the endosomal-lysosomal pathway, such as γ2-adaptin, to modulate the sorting and processing of proteins (Rüder2009The). It plays a critical role in immune function by negatively regulating the cytolytic capacity of CD8+ T cells, thereby influencing the release of cytotoxic mediators from lytic granules (Rüder2009The). This regulatory function is significant in maintaining immune homeostasis and has implications in tumor immunosurveillance and cancer progression (Miyazaki2014EBAG9).

## Function
EBAG9 is a protein involved in the regulation of immune responses and intracellular trafficking processes. It is primarily localized in the Golgi apparatus and associated vesicles, indicating a role in protein processing or trafficking within the cell (Reimer2005Reevaluation). EBAG9 interacts with γ2-adaptin, a component involved in protein sorting within the endosomal-lysosomal pathway, suggesting its involvement in the intracellular sorting and processing of proteins (Rüder2009The). This interaction implies that EBAG9 may act as an inhibitory regulator in the exocytosis process of lytic granules, particularly in cytotoxic T lymphocytes (CTLs) (Rüder2009The).

In the context of immune function, EBAG9 negatively regulates the cytolytic capacity of CD8+ T cells by modulating the release of cytotoxic mediators from lytic granules (Rüder2009The). The absence of EBAG9 enhances the sorting of lysosomal hydrolases and improves the targeting of cytolytic effector molecules like granzyme B and perforin to secretory lysosomes, leading to increased cytotoxic activity (Rüder2009The). This regulatory role suggests that EBAG9 is crucial in maintaining the balance of immune responses, potentially impacting processes such as tumor immunosurveillance (Miyazaki2014EBAG9).

## Clinical Significance
EBAG9 (estrogen receptor binding site associated antigen 9) is implicated in various cancers, including renal cell carcinoma (RCC), breast cancer, ovarian cancer, and hepatocellular carcinoma (HCC). In RCC, high EBAG9 expression is associated with advanced tumor stages, vascular infiltration, and poor prognosis, potentially due to its role in suppressing antitumor immunity and reducing CD8+ T cell infiltration (Ogushi2005Estrogen). In breast cancer, EBAG9 expression is influenced by estrogen and is linked to immune escape by inhibiting T lymphocyte infiltration (Suzuki2001EBAG9RCAS1). In ovarian cancer, EBAG9 expression correlates with advanced disease stages, although it does not significantly impact overall survival (Akahira2004Expression). In HCC, EBAG9 is associated with tumor dedifferentiation and proliferation, but not with metastasis, indicating its role in the intermediate stages of tumor progression (Aoki2003EBAG9RCAS1).

EBAG9 also acts as a negative regulator of CD8+ T cell cytolytic capacity, affecting immune responses against tumors. Its overexpression can lead to immune evasion by tumors, while its deficiency enhances CD8+ T cell activity and antitumor immunity (Rüder2009The; Miyazaki2014EBAG9).

## Interactions
EBAG9, also known as estrogen receptor-binding fragment-associated antigen 9, is involved in various protein interactions that influence cellular processes. One significant interaction is with the adaptor protein γ2-adaptin. This interaction was confirmed through yeast two-hybrid screening, GST pulldown assays, and coimmunoprecipitation studies, indicating a physical and functional relationship. The binding domain on EBAG9 for γ2-adaptin is mapped to amino acids 30-175, and this interaction is specific to the ear domain of γ2-adaptin, as it does not occur with γ1-adaptin (Rüder2009The).

EBAG9 also interacts with TM9SF1, a member of the transmembrane 9 superfamily, which is involved in autophagosome formation and is overexpressed in several cancers. This interaction was demonstrated through immunoprecipitation and fluoromicroscopy, suggesting a cooperative role in regulating cancer cell migration and epithelial-mesenchymal transition (EMT)-related gene expression (Miyazaki2018Extracellular).

Additionally, EBAG9 has been reported to associate with components of the BLOC-1 complex, such as BLOS2 and Snapin, although these interactions were not confirmed by coimmunoprecipitation experiments (Rüder2009The; Ménasché2009EBAG9). These interactions suggest a role for EBAG9 in endosomal-lysosomal sorting and immune response modulation.


## References


[1. (Aoki2003EBAG9RCAS1) T. Aoki, S. Inoue, H. Imamura, J. Fukushima, S. Takahashi, T. Urano, K. Hasegawa, T. Ogushi, Y. Ouchi, and M. Makuuchi. Ebag9/rcas1 expression in hepatocellular carcinoma. European Journal of Cancer, 39(11):1552–1561, July 2003. URL: http://dx.doi.org/10.1016/s0959-8049(03)00362-9, doi:10.1016/s0959-8049(03)00362-9. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0959-8049(03)00362-9)

[2. (Rüder2009The) Constantin Rüder, Uta E. Höpken, Jana Wolf, Hans-Willi Mittrücker, Boris Engels, Bettina Erdmann, Susanne Wollenzin, Wolfgang Uckert, Bernd Dörken, and Armin Rehm. The tumor-associated antigen ebag9 negatively regulates the cytolytic capacity of mouse cd8+ t cells. Journal of Clinical Investigation, July 2009. URL: http://dx.doi.org/10.1172/jci37760, doi:10.1172/jci37760. This article has 3 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci37760)

[3. (Reimer2005Reevaluation) Tatiana A Reimer, Ioannis Anagnostopoulos, Bettina Erdmann, Insa Lehmann, Harald Stein, Peter Daniel, Bernd Dörken, and Armin Rehm. Reevaluation of the 22-1-1 antibody and its putative antigen, ebag9/rcas1, as a tumor marker. BMC Cancer, May 2005. URL: http://dx.doi.org/10.1186/1471-2407-5-47, doi:10.1186/1471-2407-5-47. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2407-5-47)

[4. (Akahira2004Expression) J-i Akahira, M Aoki, T Suzuki, T Moriya, H Niikura, K Ito, S Inoue, K Okamura, H Sasano, and N Yaegashi. Expression of ebag9/rcas1 is associated with advanced disease in human epithelial ovarian cancer. British Journal of Cancer, 90(11):2197–2202, May 2004. URL: http://dx.doi.org/10.1038/sj.bjc.6601832, doi:10.1038/sj.bjc.6601832. This article has 37 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.bjc.6601832)

[5. (Miyazaki2018Extracellular) Toshiaki Miyazaki, Kazuhiro Ikeda, Wataru Sato, Kuniko Horie-Inoue, and Satoshi Inoue. Extracellular vesicle-mediated ebag9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression. Oncogenesis, January 2018. URL: http://dx.doi.org/10.1038/s41389-017-0022-6, doi:10.1038/s41389-017-0022-6. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41389-017-0022-6)

[6. (Ogushi2005Estrogen) Tetsuo Ogushi, Satoru Takahashi, Takumi Takeuchi, Tomohiko Urano, Kuniko Horie-Inoue, Jinpei Kumagai, Tadaichi Kitamura, Yasuyoshi Ouchi, Masami Muramatsu, and Satoshi Inoue. Estrogen receptor–binding fragment–associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Research, 65(9):3700–3706, May 2005. URL: http://dx.doi.org/10.1158/0008-5472.can-04-3497, doi:10.1158/0008-5472.can-04-3497. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-04-3497)

[7. (Suzuki2001EBAG9RCAS1) T Suzuki, S Inoue, W Kawabata, J Akahira, T Moriya, F Tsuchiya, S Ogawa, M Muramatsu, and H Sasano. Ebag9/rcas1 in human breast carcinoma: a possible factor in endocrine–immune interactions. British Journal of Cancer, 85(11):1731–1737, November 2001. URL: http://dx.doi.org/10.1054/bjoc.2001.2176, doi:10.1054/bjoc.2001.2176. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1054/bjoc.2001.2176)

[8. (Miyazaki2014EBAG9) T Miyazaki, K Ikeda, K Horie-Inoue, T Kondo, S Takahashi, and S Inoue. Ebag9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of t lymphocytes. Oncogenesis, 3(11):e126–e126, November 2014. URL: http://dx.doi.org/10.1038/oncsis.2014.40, doi:10.1038/oncsis.2014.40. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/oncsis.2014.40)

[9. (Ménasché2009EBAG9) Gaël Ménasché and Geneviève de Saint Basile. Ebag9 tempers lymphocyte killing activity. Journal of Clinical Investigation, July 2009. URL: http://dx.doi.org/10.1172/jci40270, doi:10.1172/jci40270. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci40270)